Objective: Protection of residual beta cell function at the time of diagnosis of insulin-dependent diabetes mellitus (IDDM) by intensive insulin therapy and the addition of nicotinamide (NA) has been established. The objective of this study was to evaluate the effect of a free oxygen radical scavenger such as vitamin E (Vit E) on residual beta cell function and parameters of metabolic control in patients with recent onset IDDM undergoing intensive insulin therapy. Design: The effect of Vit E was compared with that of NA (control group) in a randomized multicentre trial. Methods: Eighty-four IDDM patients between 5 and 35 years of age (mean age 15.8Ϯ8.4 (S.D.) years) entered a one year prospective study. One group of patients (n=42) was treated with Vit E (15 mg/kg body weight/day) for one year; the other group (n=42) received NA for one year (25 mg/kg body weight/day). All patients were under intensive insulin therapy with three to four injections a day. Basal and stimulated (1 mg i.v. glucagon) C-peptide secretion, glycosylated haemoglobin and insulin dose were evaluated at diagnosis and at three-monthly intervals up to one year. Results: Preservation and slight increase of C-peptide levels at one year compared with diagnosis were obtained in the two treated patient groups. No statistically significant differences were observed in basal or stimulated C-peptide levels between the two groups of patients for up to one year after diagnosis. Glycosylated haemoglobin and insulin dose were also similar between the two groups; however patients receiving Vit E under the age of 15 years required significantly more insulin than NAtreated patients one year after diagnosis (P<0.04). Conclusions: Our data indicate that Vit E and NA possess similar effects in protecting residual beta cell function in patients with recent onset IDDM. Since their putative mechanism of protection on beta cell cytotoxicity is different, combination of these two vitamins may be envisaged for future trials of intervention at IDDM onset.
Introduction
Type 1 insulin-dependent diabetes mellitus (IDDM) is the result of a selective process of damage to pancreatic beta cells ending in the lack of endogenous insulin secretion. It is now accepted that autoimmune mechanisms play an important role in the development of this disease, with beta cell destruction suggested to be mediated by a cytotoxic process involving lymphocytes and their products (1) (2) (3) . The introduction of intensive insulin therapy at clinical diagnosis of the disease (4) and the addition of immunotherapy (5) have shown transient improvements in beta cell function.
Amongst free oxygen radical scavengers which might be envisaged for adjuvant therapy at diagnosis of IDDM, vitamin E (Vit E) deserves particular attention. Vitamin E is a natural compound possessing a wide range of properties. It restores normal phagocytic functions (6) and it is efficacious in glutathione synthetase-deficient patients (7) . Vitamin E may reduce corticosteroid levels induced by stress (8) and together with vitamins A and C has been considered as a cancer preventing agent (9) as well as a free oxygen radical scavenger in several disease conditions characterized by raised oxidation processes (10, 11) .
In the case of IDDM at its initial stage, Vit E can interfere with the process of cytokine-mediated cytotoxicity acting as a free oxygen scavenger. More recently Rabinovitch et al. (12) showed that lipid peroxidation is involved in the cytotoxic effects of cytokines on rat islets and that the inhibition of lipid peroxidation protects islet beta cells from the combined effects of interleukin 1, tumour necrosis factor and interferon gamma. In the animal model of non-obese diabetic (NOD) mouse, Vit E is able temporarily to protect these mice from developing diabetes, probably by interfering with lipid peroxidation events in islet cells (13, 14) . The lack of reduction of diabetes incidence in these animals may simply be caused by the swamping of the protective mechanisms at later stages of the disease.
Based on these observations the present study was designed to test the action of Vit E on residual beta cell function in patients with recent onset IDDM. We compared its effects with those of a well known and more often used compound at this stage of the disease, nicotinamide (NA) (15) . This compound has been shown to possess in vitro beta cell protective properties (16) and, added to insulin at diagnosis, is able to improve the integrated parameters of metabolic control one year after diagnosis, especially through maintenance of residual beta cell function (17, 18) .
Patients and methods

Selection of patients
Recent onset IDDM patients were selected for this study if they fulfilled the following criteria: (i) diagnosis of the disease according to WHO criteria and with age at presentation between 5 and 35 years; (ii) duration of clinical disease (since the beginning of insulin therapy) <4 weeks; (iii) no medical contra-indications (including pregnancy) or any other major chronic disease; (iv) willing and able to participate in regular follow-up.
Design of the study
Previous studies of the IMDIAB group and a recent meta-analysis (18) have shown that nicotinamide has a protective effect on residual beta cell function when given at the time of IDDM diagnosis. After wide debate, the Steering Committee of the IMDIAB group found the use of placebo controls unacceptable in studies aimed to protect beta cell function in recent onset IDDM patients, given the satisfactory results obtained with nicotinamide (17) . This is also in line with what was recently proposed by Rothman and Michels on the continuing use of placebo controls (19) . Intensive insulin therapy is clearly the gold standard at diagnosis of IDDM but the addition of NA can be beneficial. This concept is reinforced by the results of a recent meta-analysis of the use of NA in patients with recent onset IDDM (18) . Therefore, in order to evaluate the efficacy of another compound on residual beta cell function, a comparison trial was designed. Instead of a placebo control trial we compared the effect of Vit E (test drug) and intensive insulin therapy with that of nicotinamide (known effective drug) employing the same intensive insulin therapy. Our approach has several advantages as up-todate treatment can be offered to recent onset IDDM patients and we can demonstrate whether Vit E, a potential beneficial compound in protecting beta cell destruction, has similar, better or less effect than NA on the residual beta cell function.
Investigations and follow-up
Patients enrolled in the study lived in either Rome or its Province and were followed up by the staff of the same centre where they were first seen. Each of the seven centres contributed nearly equal numbers of patients to the study.
Patients started on a 55% carbohydrate diet and received human short-acting insulin three times daily, with the addition of intermediate-acting insulin in the evening. Self-determined capillary glucose was recorded daily after fasting, and before and after meals for a total of at least 20 weekly measurements. Insulin dosage was adjusted to obtain near-normal blood glucose levels.
Patients were examined weekly for the first month of therapy and then monthly by the same team of physicians in each participating centre. Drug toxicity was evaluated at follow-up visits including liver and renal function tests and total blood count. Glycosylated haemoglobin (HbA1c) (normal range 4-7%) was measured every 3 months by a column assay (BioRad, Milan, Italy), and C-peptide secretion (basal and after 1 mg intravenous glucagon) was evaluated after hyperglycaemia was normalized before entry into the trial, and at 3-month intervals for 1 year thereafter. The stimulatory test was always performed on fasting patients in the morning and with blood glucose levels below 10 mmol/l. C-peptide was measured by radioimmunoassay using a commercially available kit (BioRad). The normal range of fasting C-peptide established in 150 healthy subjects aged 5-40 years was 1-3 ng/ml (2-5 ng/ml stimulated), with intra-and interassay coefficients of variation of 10 and 15% respectively.
Treatment protocol
After informed consent was obtained and participation in baseline studies was completed, a permuted-block design was employed to assign patients randomly in equal numbers to the two treatment groups. A random number table was adopted with a list prepared centrally and the randomization code assigned by a telephone call EUROPEAN 
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to the coordinating centre. Forty-two patients received NA at a dose of 25 mg/kg body weight (b.w.) and fortytwo patients were treated with Vit E at a dose of 15 mg/ kg b.w. This dose was calculated based upon the dose effective in protecting NOD mice from diabetes, as published elsewhere (14) . In all patients, the adjuvant therapy with Vit E or NA began within four weeks of diagnosis. None of the eligible patients refused randomization. Patients were treated with intensive insulin therapy in order to optimize metabolic control as soon as possible after diagnosis and to maintain blood glucose at levels as near normal as possible (see below).
Guidelines for insulin therapy
Participating centres used the same protocol consisting of the following rules: if pre-prandial blood glucose values were less than 6.5 mmol/l, the insulin dose was decreased by 10%; if blood glucose levels were consistently less than 4.5 mmol/l for more than 3 days, the insulin dose was decreased by 20%. Insulin therapy was not discontinued unless 2-h post-prandial blood glucose values measured at home were consistently less than 7.5 mmol/l. Patients with blood glucose values above 10 mmol/l received a 10% increase in insulin dose or had their insulin regime modified. Frequent telephone consultations were arranged with patients in order to regulate adjustments to the insulin dose.
Evaluation of response to therapy
This was monitored throughout the study by investigating the occurrence of clinical (complete) remission, defined according to the recommendations of the International Diabetes Immunotherapy Group (IDIG) as restoration of normal fasting and post-prandial blood glucose without any insulin administration for more than two weeks (20) . Moreover, the integrated measures of metabolic control (C-peptide, HbA1c and insulin dose) were analysed at 3-month intervals.
Sample size and statistical analysis
The number of patients to be included in the study was calculated from an analysis of results of trials published in the past (courtesy of IDIG Registry). Setting alpha (probability of a type I error) equal to 0.05 and beta (probability of a type II error) equal to 90%, the required sample size was 64 patients for a two-sided test. Allowing for dropouts, 42 patients were allocated in each group to ensure the appropriate sample size. Differences in clinical remission proportion between patients' groups were evaluated by one-sided Fisher's exact probability test. Results were analysed by a team of statisticians who were blind to the different treatment groups (see treatment protocol).
For the analysis of the integrated parameters of metabolic control, a repeated measure analysis of variance simultaneously for the two groups of treated patients was used; differences between treated groups at different time intervals were evaluated by the MannWhitney U test.
Results
The recruitment period lasted 1 year and 6 months. There were no significant differences between NA-and Vit E-treated patients in terms of baseline clinical characteristics and metabolic control at the time of entry into the study ( Table 1) . None of the patients suffered from any other autoimmune disease.
Metabolic outcomes during the follow-up
Glycosylated haemoglobin, insulin dose, basal and stimulated C-peptide were evaluated at diagnosis and at 3-month intervals up to 1 year. Data showed the achievement of a good metabolic control in both groups of patients: HbA1c decreased from 9.4% at entry to 6.3% after 3 months (P<0.0001) in the NA group and from 8.9% to 6.4% (P<0.005) in the Vit E group, thereafter maintaining similar levels in the two groups for up to 1 year (Table 2) . Insulin dose (IU/kg) showed a significant reduction in both groups after 3 months (NA group: 0.59 vs 0.34, P<0.0005; Vit E group: 0.50 vs 0.34, P<0.005) and remained similar in the two groups for up to 1 year (Table 2 ). These reductions in HbA1c levels and insulin doses are not different from those seen in patients treated with insulin alone in our previous experience (17) . 
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Residual beta cell function
Basal and stimulated C-peptide levels remained stable over the period of 1 year follow-up, except at 9 months from diagnosis when basal C-peptide was significantly higher in the NA-compared with the Vit E-treated patients (0.85Ϯ0.59 vs 0.67Ϯ0.55 ng/ml, P<0.005) (Mann-Whitney U test) ( Table 2) .
As the age of onset may influence the rate of beta cell destruction, the parameters of metabolic control 12 months after diagnosis are presented after subdividing the patients according to their age at diagnosis, as we had done previously (17) (Table 3) . Overall, and as expected, patients <15 years of age at diagnosis showed reduced C-peptide secretion compared with patients >15 years of age at diagnosis, irrespective of whether they were treated with NA or Vit E (P<0.001). When patients were grouped according to their age at diagnosis, there were no differences between NA-and Vit E-treated patients in respect to HbA1c and C-peptide levels; however the insulin dose required to reach the same good metabolic control as assessed by the HbA1c values in patients <15 years was significantly greater (P<0.04) in Vit E-treated compared with NA-treated patients. It is interesting to note that Vit E is as effective as NA in preserving beta cell function in patients >15 years of age.
Clinical remission
There were 4 clinical remissions in the NA group and 4 in the Vit E group (P=NS) with a mean duration of 10Ϯ8 weeks. Two patients (1 NA and 1 Vit E) were still in remission 1 year after diagnosis.
Dropouts
A total of 16 patients were withdrawn from the study. There were 9 dropouts in the NA group and 7 in the Vit E group. Reasons for dropouts were poor compliance (n=9), change in place of residence of enrolled patients (n=6) and adverse effects (n=1).
Adverse effects
Adverse effects were observed in only one Vit E patient and consisted of transient leucopenia which, however,
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Other Vit E-treated patients were monitored for white blood cell count but no leucopenia was reported.
Discussion
In this study we have demonstrated that recent onset IDDM patients treated with Vit E or NA in addition to intensive insulin therapy show similar residual beta cell function as assessed by C-peptide secretion 1 year later. The other parameters of metabolic control (HbA1c and insulin dose) were also similar between the two patient groups. The protective effects of Vit E and NA on beta cells are likely to be different. Thus, based on our knowledge of Vit E action, it is likely that the effectiveness of this vitamin at the beta cell level is due to a number of mechanisms including reducing the cytotoxicity mediated by cytokines and their products; however it does not interfere with the autoimmune process which initiates beta cell destruction as shown by its lack of effect on the insulitis process in an experimental model of the disease (13, 14) . Furthermore, one of the main routes of action of Vit E in this context is probably its effect in preventing lipid peroxidation of cell membranes, and beta cells are known to be particularly prone to peroxidative damage by free radicals, peroxidases and superoxides (3) . The antioxidant effect of Vit E also modulates the biosynthesis and activity of important cell regulators, prostaglandins, thromboxane and leukotrienes, and this vitamin also interacts positively with antioxidant micronutrients (21) . Vitamin E has been shown to decrease prostaglandin production in immune cells and to re-establish cellmediated immunity; it is one of the few nutrients for which higher than recommended amounts have been shown to restore the immune response and might be needed to maintain the optimum immune response (22) . Finally, there are several reports suggesting that patients with impaired phagocytic ability, depressed oxidative metabolic responses and bactericidial activity, and decreased chemotactic movement toward stimuli receive benefit from Vit E therapy and diabetic patients are known to be suffering from some of the above conditions (23, 24) .
Nicotinamide, apart from its long-established inhibitory effect on poly (ADP-ribose) polymerase and its ability to restore intracellular NAD+pools, has recently been found to possess other actions which may be relevant for the pathogenic process leading to IDDM. Studies with isolated islets, immune cells and their products have shown that NA protects islet cells from cell lysis after exposure to oxygen radicals or nitric oxide (16, (25) (26) (27) . Furthermore, there is evidence that NA prevents cytokine-induced MHC class II, but not class I, expression on cultured islet cells (28) and that daily administration of high doses of NA to the NOD mouse prevents or at least delays diabetes development (29) (30) (31) . Finally, a recent meta-analysis of 14 trials where NA was given to IDDM patients at diagnosis has shown that this vitamin preserves residual beta cell function as assessed by C-peptide secretion (18) .
The observation that residual beta cell function assessed by basal and stimulated C-peptide secretion in recent onset IDDM is preserved by both treatments is reinforced if one looks at the results of our previous IMDIAB trials, especially when NA was tested in a double-blind study (17) . In that trial mean basal C-peptide levels in the placebo group 1 year after diagnosis were lower than both the Vit E-and NA-treated groups of the present study. Furthermore, comparing the results of this study with those presented in the meta-analysis of the NA trials, it appears that in Vit E-treated patients, basal and stimulated C-peptide levels are similar to, if not above, those reported in the meta-analysis for NA treatment.
The next question is whether Vit E and NA are similarly effective. When we compared the two treated groups of patients some subtle differences became apparent. First, comparison of beta cell function 9 months after diagnosis showed that C-peptide secretion was significantly higher in the NA-treated patients although this effect was transient. Furthermore, patients diagnosed under the age of 15 years and receiving NA needed significantly less insulin than Vit Etreated patients 1 year after diagnosis. There is no clear explanation for these data as C-peptide secretion and HbA1c levels were similar in the two treated groups. Possible mechanisms for this observation in Vit Etreated patients, if confirmed, may include alterations in hormones involved in carbohydrate and lipid metabolism, with consequent enhanced availability of glucose (32) , thus requiring more insulin. Some other unrecognized mechanisms may also be involved.
The implications of our results are that adjuvant therapy with agents capable of protecting beta cells should be continued for well over 1 year after diagnosis, as suspension of such therapy may lead rapidly to exhaustion of residual beta cell function (33) . Furthermore, in the case of Vit E it is worth considering its effect in reducing protein non-enzymatic glycosylation in diabetic patients independently of changes in plasma glucose, an effect probably due to the inhibition of glycosylation at an early step in the Maillard reaction (34) . Therefore, Vit E might potentially be of interest in controlling the development of late diabetic complications.
In conclusion we have found that Vit E and NA are both likely to be effective in preserving beta cell function in recent onset IDDM patients up to one year after diagnosis. Both compounds have minimal adverse effects and, since the two vitamins may act at different levels in the process leading to beta cell destruction, a combination of these two vitamins may be considered for future trials conducted at diagnosis of the disease.
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